Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus (Q38151450)

29 August 2017

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus (English)

1 reference

29 August 2017

1 reference

Anthony H Barnett

1

1 reference

PubMed ID

24113667

29 August 2017

language of work or name

English

0 references

publication date

1 September 2013

1 reference

29 August 2017

Postgraduate Medicine

1 reference

29 August 2017

125

1 reference

29 August 2017

92-100

1 reference

29 August 2017

5

1 reference

IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030

29 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Prevalence, predisposition and prevention of type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

The challenge of managing coexistent type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

The prevention and treatment of obesity. Application to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Benefits of moderate weight loss in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Intentional weight loss and mortality among overweight individuals with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Obesity medications and the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Standards of medical care in diabetes--2012

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Bariatric surgery: an IDF statement for obese Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Weight change in diabetes and glycemic and blood pressure control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Incretin therapy and its effect on body weight in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Patient adherence to medication requirements for therapy of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

The impact of treatment noncompliance on mortality in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Polypharmacy and Medication Adherence in Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Comment on: Vila et al. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes 2012;61:2592-2596.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Loss of Pdk1-Foxo1 signaling in myeloid cells predisposes to adipose tissue inflammation and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Role of TRIB3 in diabetic and overnutrition-induced atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Comment on: Winkler et al. Histone deacetylase 6 (HDAC6) is an essential modifier of glucocorticoid-induced hepatic gluconeogenesis. Diabetes 2012;61:513-523.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Medication Adherence Affects Treatment Modifications in Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.09.2698

21 January 2018

Identifiers

DOI

10.3810/PGM.2013.09.2698

1 reference

29 August 2017

1 reference

PubMed ID

24113667